News and Views


Nature Chemical Biology 4, 91 - 93 (2008)
doi:10.1038/nchembio0208-91

Losing inhibition with ketamine

Jeremy Seamans1

  1. Jeremy Seamans is in the Department of Psychiatry and the Brain Research Centre at the University of British Columbia, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 2B5, Canada. e-mail: seamans@interchange.ubc.ca


Schizophrenia is thought to involve a dysfunction of glutamatergic and GABAergic signaling in the prefrontal cortex, but how these systems interact in the disease has been unclear. Now ketamine, a glutamatergic NMDA receptor antagonist, may provide a mechanism that could link these pathways.

Top


MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Interneurons and the ghost of the sea

Nature Neuroscience News and Views (01 Oct 1998)

Synchronous versus asynchronous transmitter release: a tale of two types of inhibitory neurons

Nature Neuroscience News and Views (01 Oct 2005)


Extra navigation

Subscribe to Nature Chemical Biology

Subscribe

Search PubMed for

Open Innovation Challenges